Our Discovery
Platform
Combining open-source DNA-encoded libraries (DEL), proprietary one-of-a-kind focus DEL, computational chemistry, and artificial intelligence to discover novel small-molecule therapeutics with unparalleled efficiency and precision.
22 billion
compounds in our DEL collection
140+
DNA-encoded libraries
Proprietary
FocusDEL™ technology
Our Integrated Discovery Platform
We combine cutting-edge technologies to identify novel, potent compounds with superior drug-like properties.
Accelerating Discovery Through Complementary Technologies
Accelerated Timelines
Our integrated approach significantly reduces the time from target identification to lead compound selection.
Cost-Effective R&D
By combining complementary methods, we optimize resource allocation and reduce overall development costs.
DNA-Encoded Libraries
DNA-Tagged Compounds
Molecules are tagged with unique DNA barcodes that allow tracking of billions of compounds.
FocusDEL™
We generate proprietary, one-of-a-kind DEL that enable precision discovery and enrich for target-specific hits.
Target Binding
Tagged compounds are exposed to protein targets to identify potential therapeutic molecules.
Hit Identification
DNA sequencing reveals which compounds bound to the target, allowing rapid identification of hits.
Scouring the Chemical Universe
DNA-encoded library (DEL) screening is an effective hit-finding technique demonstrated to work across many medicinally relevant targets. This approach allows us to cost-effectively screen billions of compounds simultaneously, dramatically increasing our chances of finding novel therapeutic candidates.
Some drug discovery teams use internal DEL synthesis efforts to generate proprietary libraries; others rely on DEL vendors. At Orogen, we utilize both approaches to maximize our chemical diversity.
Building the Orogen DEL Platform
At Orogen, we utilize an immense array of chemistries from commercially available 2- and 3-cycle libraries. Our collection of ~180 libraries cataloging over 22 billion compounds exhibits impressive chemical diversity with many unique features.
This diversity drives efficient small molecule selection against different targets to effectively identify drug discovery starting points. The output from these screens is subjected to next-generation sequencing and then bioinformatically analyzed to identify the enriched features.
Fun Fact: 22 billion compounds is more than 2x the number of people on Earth!
FocusDEL™
While standard DNA-encoded libraries afford certain scale advantages, they are in principle so broad that they can be inefficient and potentially miss key binders among the hits initially found. This not only can increase costs and time in screening campaigns, it can also reduce overall probabilities of success.
A New Frontier in DEL
To overcome these challenges, Orogen is pioneering a unique approach in which one-of-a-kind DEL are purpose-built to focus on a specific target. We call these proprietary focused DNA-Encoded Libraries "FocusDEL™".
FocusDEL™ are versions of DELs constructed from existing DEL libraries that have reactive handles of different natures by attaching additional chemical moieties (baits) selected as building blocks designed for a specific target. With suitable baits, FocusDEL™ can explore the relevant chemical space while directly binding to the target of interest.
FocusDEL™ Technology
Efficient Drug Design and Synthesis
Orogen's medicinal chemistry approach is guided by our multi-parameter optimization strategy, which balances potency, selectivity, safety, and drug-like properties to design effective therapeutics.
Our team's deep expertise in computational chemistry, structure-based design, and synthetic organic chemistry enables us to rapidly identify and optimize promising compounds with the potential to address significant unmet medical needs.
Chemistry Workflow
Hit Identification
Discover promising molecules from our DEL and virtual screening platforms
Compound Design
Optimize structure and properties using computational chemistry
Compound Synthesis
Create new compounds using our advanced synthesis capabilities
Lead Optimization
Refine compounds to improve efficacy, safety, and drug-like properties
AI-poweredTarget Analysis
Our computational chemistry platform combines deep learning algorithms with traditional physics-based methods to accelerate drug discovery.
By applying sophisticated machine learning models to analyze protein structures and predict binding affinities, we can rapidly identify the most promising compound candidates before synthesis.
Virtual Screening
Structure-Based Screening
Analyzing protein-ligand interactions to predict binding affinities and identify compounds likely to bind to a specific target.
Deep Learning Models
Neural networks trained on millions of data points to predict binding affinity, pharmacological properties, and potential off-target effects.
Quantitative Structure-Activity Relationship
Statistical models that predict biological activity based on physical and chemical properties of compounds.
Key Advantages
- Screens millions of compounds in days instead of months
- Identifies novel scaffolds that may be missed by traditional methods
- Reduces experimental costs by prioritizing the most promising compounds
- Optimizes multiple parameters simultaneously (potency, selectivity, safety)
- Accelerates hit-to-lead and lead optimization phases
Modeling Technology
Hybrid Approach
Combining ML algorithms with biophysical models
Protein Structure Prediction
Accurate 3D models of target proteins for structure-based drug design
Molecular Dynamics Simulations
Analyzing protein motion and conformational changes for enhanced target understanding
Pharmacophore Modeling
Identifying essential features needed for optimal interaction with target proteins
Our Collaborative Partners
Discover the Orogen Pipeline
The Orogen Pipeline integrates advanced AI, machine learning, and proprietary chemistry to accelerate the discovery of novel therapeutics. Explore how our end-to-end approach transforms target analysis into real-world breakthroughs.
"Orogen is elevating new heights in drug discovery, integrating massive chemical libraries, target-specific screening, and AI-based computation to propel the generation of novel medicines."
Mark Pykett
CEO, Orogen Therapeutics